Biosimilars· June 29, 2026 · 18 min read
Soliris Biosimilar Cliff: NMOSD Exclusivity Expiry and Payer Step Edits
By Ran Chen#Biosimilars#Interchangeability#Payer Policy
Topic
Interchangeability
FDA interchangeability, pharmacy substitution, state-law boundaries, and what the designation does and does not mean commercially.
Biosimilars· June 21, 2026 · 6 min read
Soliris NMOSD Exclusivity Expiration: Skinny Label & REMS Barriers for Bkemv
Biosimilars· June 16, 2026 · 11 min read
Interchangeable biosimilars in the Purple Book: 46 products, 12 reference biologics
By Ran Chen#Biosimilars#Interchangeability#Purple Book
Biosimilars· June 7, 2026 · 8 min read
Langlara insulin glargine biosimilar: interchangeable Lantus, formulary, and switching
Biosimilars· June 1, 2026 · 12 min read
FDA biosimilar interchangeability without switching studies: the 2026 pathway
By Ran Chen#Biosimilars#Interchangeability#FDA Approval
Biosimilars· May 31, 2026 · 12 min read
Interchangeable biosimilar substitution notices and state-law workflow
By Ran Chen#Biosimilars#Interchangeability#Payer Policy
Biosimilars· May 27, 2026 · 11 min read
Lantus biosimilars and insulin glargine interchangeability guide
Biosimilars· May 27, 2026 · 9 min read
Simponi and Simponi Aria biosimilars guide
By Ran Chen#Biosimilars#TNF Inhibitor#Immunology
Biosimilars· May 27, 2026 · 11 min read
Xolair and Omlyclo omalizumab access guide
Biosimilars· May 21, 2026 · 8 min read